Form 4: Maravai Lifesciences Executive Sells Shares for Tax

Christine Dolan, EVP & General Manager of Cygnus Technologies, disposed of 28,661 Maravai Lifesciences shares to cover tax obligations from restricted stock unit vesting.

Summary

• Christine Dolan, Executive Vice President & General Manager of Cygnus Technologies, a subsidiary of Maravai Lifesciences Holdings, Inc., reported a transaction on March 16, 2026.
• The transaction involved the disposition of 28,661 shares of Class A Common Stock.
• These shares were withheld to satisfy tax withholding obligations related to the vesting of restricted stock unit awards.
• The shares were disposed of at a price of $3.08 per share.
• Following this transaction, Christine Dolan beneficially owns 420,312 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine, non-discretionary transaction for tax withholding purposes, which typically has a neutral impact on market sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that tax-related dispositions of shares by executives are common and routine events in the life sciences industry, often occurring upon the vesting of restricted stock units or other equity awards. These transactions are typically non-discretionary and are not usually indicative of a change in management's outlook on the company's performance or stock value.

Comparison to Industry Standards

• This type of transaction (shares withheld for tax obligations upon RSU vesting) is a standard practice across publicly traded companies, including those in the biotechnology and life sciences sectors, such as Thermo Fisher Scientific or Danaher Corporation, where executive compensation often includes equity awards.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not a discretionary sale indicating a change in management's outlook.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

Maravai Lifesciences, MRVI, Christine Dolan, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation